CorVel Corporation (Nasdaq: CRVL) — Form 10-K summary
Period clarification: The supplied filing is CorVel’s annual report for the fiscal year ended March 31, 2023, not a 2021 Q4 filing. It also reports FY2023 fourth-quarter results for the three months ended March 31, 2023.
Business context and reporting period
CorVel provides workers’ compensation, auto and group-health claims management and medical cost-containment services to insurers, third-party administrators, employers and government entities. Its services include claims and case management, bill review, provider networks, pharmacy, utilization management and directed care. The company reports one operating segment, managed care.
FY2023 revenue was 66.6% patient management and 33.4% network solutions. No customer accounted for 10% or more of annual revenue; one customer represented at least 10% of accounts receivable.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $718.6 million | $646.2 million |
| Gross profit / margin | $158.3 million / 22.0% | $152.1 million / 23.5% |
| Income before taxes | $84.6 million | $84.5 million |
| Net income / margin | $66.4 million / 9.2% | $66.4 million / 10.2% |
| Diluted EPS | $3.77 | $3.66 |
| Operating cash flow | $82.3 million | $67.2 million |
| Cash used for property and equipment | $26.3 million | $29.8 million |
| Cash and cash equivalents at year-end | $71.3 million | $97.5 million |
| Working capital at year-end | $75.9 million | $93.6 million |
Patient management revenue rose 13% to $478.8 million, primarily from TPA and related services; total new claims increased 5%. Network solutions revenue rose 8% to $239.8 million, reflecting higher revenue per bill from enhanced bill-review programs. Cost of revenue increased 13%, including a 15% increase in salaries; field-operations average headcount rose 10%. General and administrative expense increased 9% to $73.7 million, mainly from legal costs related to data-privacy compliance and corporate systems spending.
The company reported virtually no interest-bearing debt for the past 32 years. At March 31, 2023, total liabilities were $191.7 million, including $33.8 million of lease liabilities; current assets were $243.8 million and current liabilities were $167.9 million. Management said cash and expected internally generated funds should cover expected requirements for at least 12 months. Net cash used in financing was $82.1 million, mainly reflecting share repurchases.
FY2023 Q4 revenue was $185.4 million, gross profit $42.0 million, net income $18.2 million, and diluted EPS $1.04. The filing does not provide a clear standalone quarterly cash-flow or balance-sheet value.
Material changes versus the prior year
- Revenue grew 11.2%, slower than FY2022’s 16.9% growth. Gross profit grew 4.0%, while pretax income was nearly unchanged and net income declined slightly.
- Gross margin fell to 22.0% from 23.5%; pretax margin declined to 11.7% from 13.0%, and net margin to 9.2% from 10.2%. Higher labor costs and headcount were key pressures.
- Operating cash flow improved by $15.1 million, which management attributed principally to revenue growth and flat accounts receivable due to strong collections.
- Cash decreased by $26.2 million. The company spent $93.7 million to repurchase 598,241 shares, compared with $90.1 million and 566,073 shares in FY2022. Diluted weighted-average shares fell 3.0% to 17.6 million.
- Working capital declined by $17.7 million, primarily due to increased share-repurchase spending. The company also reduced its expected office footprint as more employees work remotely, lowering right-of-use assets and lease liabilities.
Outlook, risks and unusual items
The filing provides no formal revenue or earnings guidance. Management expects cash on hand and anticipated operating cash flows to fund obligations and planned business needs for at least 12 months, and said repurchases may continue if cash generation permits; the program may be reduced or stopped if earnings or cash flows weaken. The company paid $10.4 million of payroll taxes previously deferred under the CARES Act, with the remaining half paid in the December 2022 quarter.
Management cited inflation in wages, benefits and other costs, competitive pricing pressure, and the possibility that inflation could materially affect future pricing and expenses, although it did not consider the FY2023 impact material to revenue or net income. Key risks include lower workers’ compensation claim volumes, customer contract losses or reduced outsourcing, competition and insourcing, labor availability and cost, technology investment and obsolescence, cybersecurity and privacy incidents, regulatory changes, and litigation or professional liability. Ordinary-course legal matters were not expected by management to result in aggregate payments material to financial position or results.
The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting. Revenue recognition was identified as a critical audit matter, particularly estimates for certain bill-review services and period-end directed-care services. No goodwill or long-lived-asset impairment was identified at year-end.
Important facts for investors to verify
- Confirm the intended period: this source covers FY2023 and FY2023 Q4, not 2021 Q4.
- Review whether TPA and new-claims growth can continue, and whether patient-management and network-solutions trends remain balanced.
- Track labor-cost growth against revenue growth and monitor gross-margin recovery.
- Assess cash conversion, working-capital movement, customer deposits and the impact of ongoing repurchases on liquidity.
- Review the assumptions behind variable bill-review and directed-care revenue estimates, the auditor’s critical audit matter.
- Monitor customer concentration in receivables, data-privacy and cybersecurity exposure, regulatory developments, and legal or insurance-liability contingencies.